• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Specific immunotherapy against cancer using adenocarcinoma restricted antigen peptide that is recognized by human monoclonal antibody.

Research Project

Project/Area Number 11671150
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field General surgery
Research InstitutionChiba University

Principal Investigator

TAKIGUCHI Nobuhiro (2000)  Chiba University, School of Medicine, Assistant, 医学部, 助手 (00261917)

若月 一雄 (1999)  千葉大学, 医学部・附属病院, 助手 (60302543)

Co-Investigator(Kenkyū-buntansha) ODA Kenji  Chiba University, University Hospital, Assistant, 医学部・附属病院, 助手 (90282483)
YASUTOMI Jun  Chiba University, University Hospital, Assistant, 医学部・附属病院, 助手 (30323421)
滝口 伸浩  千葉大学, 医学部・附属病院, 助手 (00261917)
Project Period (FY) 1999 – 2000
Project Status Completed (Fiscal Year 2000)
Budget Amount *help
¥3,000,000 (Direct Cost: ¥3,000,000)
Fiscal Year 2000: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 1999: ¥1,700,000 (Direct Cost: ¥1,700,000)
KeywordsHuman Monoclonal Antibody / cancer associated antigen / cDNA cloning / colon cancer / AgSK1 / specific immunotherapy / cytotoxic T lymphocyte / peptide vaccine / 細胞障害性T細胞(CTL) / ペプチド抗原 / 抗イディオタイプ抗体 / 細胞傷害性T細胞(CTL) / 癌ワクチン
Research Abstract

SK1, a human IgM monoclonal antibody recognizes the antigen, termed AgSK1, which was shown to be preferentially expressed by human adenocarcinomas, particularly human gastrointestinal malignancies (Bt.J.Camcer 78, 1313-22, 1998). Recently, we screened a cDNA expression library constructed using mRNA from a colon carcinoma cell line HT29 and isolated a partial cDNA clone designated AgSK1-2HT ( Tissue Antigens 55, 157-61, 2000). This clone consisted of an amino terminal open reading frame of 54 amino acids and the carboxyl terminal 20 amino acids of this coding region contained the antigenic epitope recognized by SK1. In order to show additional evidence for our claim that the identified peptide was the main antigenic epitope recognized by SK1, we tried to determine a full length cDNA sequence of this clone. Searching the nonredundant and EST database using the BLAST program, we found a clone DJ1129D05 that contained a highly homologous fragment to the coding region of AgSK1-2HT.According to the sequence of this clone, we PCR amplified several overlapping fragments using mRNA from a human colon carcinoma cell line LoVo and directly sequenced them. Assembly of these sequences yielded the entire coding sequence of AgSK1-2HT that seemed have 387 nucleotides encoding 129 amino acid peptide ( NCBI Gen Bank accession number AF316855 and AAK15476). We also found that this clone consisted of 9-mer and 10-mer peptide which carried the strong allele specific anchor residues to HLA-A2402 and HLA-A0201 respectively. We are now trying to induce CTL using these peptides in vitro. Although we should further analyze these peptides, AgSK1-2HT may be utilized as a useful cancer vaccine.

Report

(3 results)
  • 2000 Annual Research Report   Final Research Report Summary
  • 1999 Annual Research Report
  • Research Products

    (15 results)

All Other

All Publications (15 results)

  • [Publications] Yasutomi,J. et al.: "Identification of the immunoreactive peptide sequence for AgSK1, an adenocarcinoma-restricted antigen."Tissue Antigens. 55(2). 157-161 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Yasutomi,J. et al.: "Antigen characterization and therapeutic uses of SK1, a human monoclonal antibody to adenocarcinomas."Proceedings of the American Association for Cancer Research. 41. 700 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Soda,H.et al.: "Adoptive immunotherapy for advanced cancer patients using in vitro activated cytotoxic Tlymphocytes."Journal of Surgical Oncology. 72(4). 211-217 (1999)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Glassy,M. et al.: "Lessons learned about the therapeutic potential of the natural human immuneresponse to lung cancer."Exp.Opin.Invest.Drugs. 8(7). 995-1006 (1999)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Jun Yasutomi, et al.: "Identification of the Immunoreactive Peptide Sequence for AgSK1, an Adenocarcinoma-Restricted Antigen."Tissue Antigens. 55. 157-61 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Jun Yasutomi et al.: "Antigen characterization and therapeutic uses of SK1, a human monoclonal antibody to adenocarcinomas."Proceedings of the American Association for Cancer Research. 41. 700 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Hiroaki Soda et al.: "Adoptive Immunotherapy for Advanced Cancer Patients Using In Vitro Activated Cytotoxic T Lymphocytes."J.Surg.Oncol.. 72. 211-7 (1999)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Mark C.Glassy et al.: "Lessons learned about the therapeutic potential of the natural human immune response to lung cancer."Exp.Opin.Invest.Drugs. 8. 995-1006 (1999)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Yasutomi,J. et al.: "Identification of immunoreactive peptide sequence for AgSK1, an adenocarcinoma-restricted antigen."Tissue Antigens. 55(2). 157-161 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] Yasutomi,J. et al.: "Antigen characterization and therapeutic uses of SK1, a human monoclonal antobodies to adenocarcinomas."Proceedings of the American Association for Cancer Research. 41. 700 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] Soda,H. et al.: "Adoptive immunotherapy for advanced cancer patients using in vitro activated cytotoxic Tlymphocytes."Journal of Surgical Oncology. 72(4). 211-217 (1999)

    • Related Report
      2000 Annual Research Report
  • [Publications] Glassy,M. et al.: "Lessons learned about the therapeutic potential of the natural human immune response to lung cancer."Exp.Opin.Invest.Drugs. 8(7). 995-1006 (1999)

    • Related Report
      2000 Annual Research Report
  • [Publications] J. Yasutomi et al.: "Identification of the immunoreactive peptide sequence for AgSK1, an adenocarcinoma-restricted antigen"Tissue Antigens. 55・2. 157-161 (2000)

    • Related Report
      1999 Annual Research Report
  • [Publications] H. Soda et al.: "Adoptive Immunotherapy for Advanced Cancer Patients Using In Vitro Activated Cytotoxic T Lymphocytes"Journal of Surgical Oncology. 72. 211-217 (1999)

    • Related Report
      1999 Annual Research Report
  • [Publications] Mork C Alassy et al.: "Lessons learned about the therapentic potential of the ratural human immune response to lung cancer"Exp. Opin. Invest. Drugs. 8(7). 995-1006 (1999)

    • Related Report
      1999 Annual Research Report

URL: 

Published: 1999-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi